Self-reported alcohol intake and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study

Erin E Wetherbee, Dennis E Niewoehner, Joseph H Sisson, Sarah M Lindberg, John E Connett, Ken M Kunisaki, Erin E Wetherbee, Dennis E Niewoehner, Joseph H Sisson, Sarah M Lindberg, John E Connett, Ken M Kunisaki

Abstract

Objective: To evaluate the relationship between alcohol consumption and the risk of acute exacerbation of COPD (AECOPD).

Methods and measurements: We conducted a secondary analysis of data previously collected in a large, multicenter trial of daily azithromycin in COPD. To analyze the relationship between amount of baseline self-reported alcohol consumption in the past 12 months and subsequent AECOPD, we categorized the subjects as minimal (<1 drink/month), light-to-moderate (1-60 drinks/month), or heavy alcohol users (>60 drinks/month). The primary outcome was time to first AECOPD and the secondary outcome was AECOPD rate during the 1-year study period.

Results: Of the 1,142 enrolled participants, 1,082 completed baseline alcohol questionnaires and were included in this analysis. Six hundred and forty-five participants reported minimal alcohol intake, 363 reported light-to-moderate intake, and 74 reported heavy intake. There were no statistically significant differences in median time to first AECOPD among minimal (195 days), light-to-moderate (241 days), and heavy drinkers (288 days) (P=0.11). The mean crude rate of AECOPD did not significantly differ between minimal (1.62 events per year) and light-to-moderate (1.44 events per year) (P=0.095), or heavy drinkers (1.68 events per year) (P=0.796). There were no significant differences in hazard ratios for AECOPD after adjustment for multiple covariates.

Conclusion: Among persons with COPD at high risk of exacerbation, we found no significant relationship between self-reported baseline alcohol intake and subsequent exacerbations. The number of patients reporting heavy alcohol intake was small and further study is needed to determine the effect of heavy alcohol intake on AECOPD risk.

Trial registration: ClinicalTrials.gov NCT00325897.

Keywords: alcohol; alcoholism; chronic obstructive; ethanol; pulmonary disease.

Figures

Figure 1
Figure 1
Alcohol use questionnaire.
Figure 2
Figure 2
Proportion free from AECOPD for 1 year, according to alcohol consumption pattern. Abbreviation: AECOPD, acute exacerbation of chronic obstructive pulmonary disease.

References

    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
    1. US Burden of Disease Collaborators The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591–608.
    1. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD J Chronic Obstr Pulm Dis. 2006;3(4):211–218.
    1. National Heart Lung and Blood Institute . Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart Lung and Blood Institute; 2012.
    1. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.
    1. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164(3):358–364.
    1. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931.
    1. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
    1. Szabo G, Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res. 2009;33(2):220–232.
    1. Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc. 2005;2(5):428–432.
    1. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2010;138(12):1789–1795.
    1. Fernández-Solá J, Junqué A, Estruch R, Monforte R, Torres A, Urbano-Márquez A. High alcohol intake as a risk and prognostic factor for community-acquired pneumonia. Arch Intern Med. 1995;155(15):1649–1654.
    1. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med. 2004;140(3):211–219.
    1. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.
    1. Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med. 2013;166(22):2437–2445.
    1. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698.
    1. Sisson JH, Stoner JA, Romberger DJ, et al. Alcohol intake is associated with altered pulmonary function. Alcohol. 2005;36(1):19–30.
    1. Tabak C, Smit HA, Räsänen L, et al. Alcohol consumption in relation to 20-year COPD mortality and pulmonary function in middle-aged men from three European countries. Epidemiology. 2001;12(2):239–245.
    1. Reilly KH, Gu D, Duan X, et al. Risk factors for chronic obstructive pulmonary disease mortality in Chinese adults. Am J Epidemiol. 2008;167(8):998–1004.
    1. Jones PW. Quality of life measurement for patients with diseases of the airways. Thorax. 1991;46(9):676–682.
    1. Make B, Casaburi R, Leidy NK. Interpreting Results from clinical trials: understanding minimal clinically important differences in COPD outcomes. COPD J Chronic Obstr Pulm Dis. 2005;2(1):1–5.
    1. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis. 1992;145:1321–1327.
    1. Nowak C, Sievi NA, Clarenbach CF, et al. Accuracy of the hospital anxiety and depression scale for identifying depression in chronic obstructive pulmonary disease patients. Pulm Med. 2014;2014:1–7.
    1. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. an updated literature review. J Psychosom Res. 2002;52(2):69–77.
    1. Sisson JH. Alcohol and airways function in health and disease. Alcohol. 2007;41(5):293–307.
    1. Kornum JB, Due KM, Nørgaard M, et al. Alcohol drinking and risk of subsequent hospitalisation with pneumonia. Eur Respir J Off J Eur Soc Clin Respir Physiol. 2012;39(1):149–155.
    1. Loeb M, Neupane B, Walter SD, et al. Environmental risk factors for community-acquired pneumonia hospitalization in older adults. J Am Geriatr Soc. 2009;57(6):1036–1040.
    1. Pai JK, Hankinson SE, Thadhani R, Rifai N, Pischon T, Rimm EB. Moderate alcohol consumption and lower levels of inflammatory markers in US men and women. Atherosclerosis. 2006;186(1):113–120.
    1. Greene CC, Bradley KA, Bryson CL, et al. The association between alcohol consumption and risk of COPD exacerbation in a veteran population. Chest. 2008;134(4):761–767.
    1. Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the science and challenges for research. Addiction. 2003;98(Suppl 2):1–12.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren